The Roche group expects sales this year to increase by a low-to mid-single digit percentage at constant exchange rates, despite headwinds from the coronavirus pandemic. Like other pharma companies, Roche’s sales were hit in the second quarter as patients cancelled routine hospital visits in order to comply with lockdown restrictions. This impacted sales of the company’s multiple sclerosis drug Ocrevus; the haemophilia drug Hemlibra; the eye treatment Lucentis; and the cancer treatment MabThera.
